Quiroga, BorjaSoler, Maria JoseOrtiz, AlbertoOrero, EstherTejedor, SandraJarava-Mantecon, Carlos JesusGomez-Perez, Virginia OlindaMarin-Franco, Antonio JoseAlfaro-Sanchez, ChristianPuerta-Carretero, MartaJaldo-Rodriguez, Maria TeresaCarnerero-Di-Riso, Manuel AntonioMartinez, ShairaCaldeon-Gonzalez, CarmenCervienka, MichalMacias-Carmona, NicolasArroyo, DavidPerez-Del-Valle, Katia Mde-Arriba, GabrielMazuecos, AuxiliadoraCazorla, Juan ManuelPereira, MonicaGonzalez-Parra, EmilioSanchez-Marquez, Maria GabrielaLancho-Novillo, CarolinaToyos-Ruiz, CarmenAguilar-Cervera, Maria CintaMuñoz-Ramos, PatriciaSanchez-Horrillo, AnaJimeno-Martin, IsabelToapanta, NestorCigarran-Guldris, SecundinoFolgueiras-Lopez, MontserratValero-San-Cecilio, RosaliaVillacorta-Linaza, BlancaMinguela-Pesquera, IgnacioSantana-Estupiñan, RaquelZamora, RocioSoriano, SagrarioMuñoz-de-Bustillo, EduardoPizarro-Sanchez, Maria SoledadMartinez-Puerto, Ana IsabelYugueros, AlejandraMuñiz-Pacios, LauraLeyva, AlbaRojas, JoseGansevoort, Ron Tde-Sequera, Patricia2023-05-032023-05-032022-05-12Quiroga B, Soler MJ, Ortiz A, Orero E, Tejedor S, Mantecón CJJ, et al. Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. Clin J Am Soc Nephrol. 2022 Jun;17(6):872-876http://hdl.handle.net/10668/20489Information on the effect of a third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in advanced CKD is incomplete (1). We assessed the humoral response up to 6 months after receipt of two or three doses of the SARS-CoV-2 vaccine across the CKD spectrum. SENOVAC is a prospective, multicentric study of cohorts of patients with CKD: kidney transplant, hemodialysis (HD), peritoneal dialysis (PD), and nondialysis CKD (eGFR <30 ml/min per 1.73 m2) (2,3). Patients were vaccinated against SARS-CoV-2 during routine clinical care. Some patients received a third dose of an mRNA vaccine. This depended on the timing of vaccination drives by local health authorities. We assessed anti-Spike antibodies (CLIA, Covid-19 Spike Quantitative Virla IgG Monotest; Vircell SL, Spain) kinetics at a prespecified 6-month time point after completing the original vaccination schedule (2,3). The study was approved by the ethics committee of Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (ISFJD) (February 2021).enCOVID-19SARS-CoV-2Anti-SpikeChronic kidney diseaseHemodialysisKidney transplantationPeritoneal dialysisVaccinationAntibodies, ViralCOVID-19COVID-19 VaccinesHumansImmunity, HumoralRenal DialysisRenal Insufficiency, ChronicSARS-CoV-2Vaccinationresearch article35551070Restricted AccessEnfermedad renal crónicaVacuna contra SARS-CoV-2Trasplante renalHemodiálisisPeritoneodiálisisAnticuerpos anti-Spike10.2215/CJN.017702221555-905XPMC9269649https://pure.rug.nl/ws/files/227235228/872.full.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269649/pdf